DelveInsight’s ‘Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035’ report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: by 2035
Neoantigen-based Personalized Cancer therapeutic Vaccines Understanding
Neoantigen-based Personalized Cancer therapeutic Vaccines Overview
Cancer vaccines use weakened or killed viruses, bacteria, or other infection-causing agents to initiate an immune response in the body. These vaccines are designed to work similarly, wherein the immune system will recognize, attack, and destroy cancer cells. They identify cancer cells as foreign, and therefore, prepare the immune system to attack the cancer cells. Cancer vaccines are one way to utilize the body’s immune system to fight cancer.
Neoantigens that arise from cancer-specific mutations represent another class of attractive antigens for therapeutic cancer vaccines. Vaccination against the tumor-specific neoantigens minimizes the potential induction of central and peripheral tolerance as well as the risk of autoimmunity. Neoantigen-based cancer vaccines have recently showed marked therapeutic potential in both preclinical and early-phase clinical studies.
Tumor-specific antigens, also termed as neoantigens, are derived from random somatic mutations in tumor cells and not present in normal cells. Compared to those non-mutated self-antigens, neoantigens could be recognized as non-self by the host immune system and are thus attractive targets for immunotherapies with potentially increased specificity, efficacy, and safety.
Request for sample pages: https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape
Neoantigen-based Personalized Cancer therapeutic Emerging Vaccines
• Tedopi (OSE2101): OSE Immunotherapeutics
OSE Immunotherapeutics’ lead clinical immune-oncology asset is Tedopi, which is neoantigen-based immunotherapy in development for the treatment of HLA-A2+ NSCLC. It contains a combination of 10 optimized neo-epitopes, which are parts of proteins that structurally alter cancer cells and trigger strong immune responses against them. The epitopes present in Tedopi are optimized from five tumorous antigens. The epitopes express a minimum of one of the tumor antigens and generate a specific response from cytotoxic (aka killer) T-cells against cancer cells. Tedopi works by stimulating killer T-cells, enabling them to spot and eliminate cancerous cells, which is a key process in the treatment of disease. Currently, the vaccine is in phase III stage of clinical development for Non-small Cell Lung Cancer.
• GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology
Gritstone Oncology is developing a combination vaccine product; wherein, GRANITE is personalized neoantigen-based immunotherapy. It is engineered to elicit a significant T-cell response (particularly CD8+ cytotoxic T-cells) against mutation-derived tumor-specific neoantigens, or TSNA, identified for each patient through the company’s proprietary EDGE machine learning-based platform. It consists of two components, first an adenoviral priming vector followed by monthly boosting with an RNA vector, each containing the same 20 patient-specific TSNA. On the other hand, SLATE will utilize the same antigen delivery system as GRANITE but includes a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing with an off-the-shelf alternative to GRANITE. Currently, the vaccine combination is in phase I/II stage of clinical development for multiple cancer indications such as Colorectal Cancer, Urothelial Carcinoma, and others.
Further product details are provided in the report…
Neoantigen-based Personalized Cancer therapeutic Vaccines Therapeutic Assessment
This segment of the report provides insights about the different emerging vaccines segregated based on following parameters that define the scope of the report, such as:
• Major Key Players
• Phases
• Route of Administration
• Target Indications of various Vaccines
Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Outlook
The Neoantigen-based Personalized Cancer therapeutic Vaccines market outlook of the report helps in building the detailed understanding of the forecasted Cancer therapeutic Vaccines market by analyzing the therapeutic vaccines based on its promising safety and efficacy results, extent of T-cell responses, tolerability, extent of tumor reduction, extent of recurrence reduction, improvement in median overall survival rate, improvement in progression free survival rate, degree of overcoming unmet needs, market drivers and barriers along with promising novel technologies.
According to DelveInsight, Neoantigen-based Personalized Cancer Therapeutic Vaccines market in 7MM is expected to change in the study period by 2035.
Neoantigen-based Personalized Cancer Therapeutic Vaccines Uptake
This section focusses on the emerging vaccines of the Neoantigen-based Personalized Cancer Therapeutics, which will get launched in the market during the study period by 2035. The analysis covers Neoantigen-based Personalized Cancer Therapeutic Vaccines market, patient uptake by therapies, and sales of each vaccine.
This helps in understanding the vaccines with the most rapid uptake, reasons behind the maximal use of new vaccines, and allows the comparison of the vaccines on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Download sample pages: https://www.delveinsight.com/sample-request/neoantigen-based-personalized-cancer-therapeutic-vaccines-competitive-landscape
Scope of the Report
- The report covers the descriptive overview of Neoantigen-based Personalized Cancer therapeutic Vaccines.
- Comprehensive insight has been provided into the Neoantigen-based Personalized Cancer therapeutic Vaccines for several cancer indications and treatment in the 7MM.
- Additionally, an all-inclusive account of emerging vaccines for Neoantigen-based Personalized Cancer therapeutic Platform are provided, along with the assessment of new therapies, which will have an impact on the market.
- A detailed review of Neoantigen-based Personalized Cancer therapeutic Vaccines market; forecasted is included in the report, covering vaccine outreach in the 7MM.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neoantigen-based Personalized Cancer Therapeutic Vaccines market.
Table of contents:
1. Key Insights
2. Executive Summary of Neoantigen-based Personalized Cancer therapeutic Vaccines
3. Competitive Intelligence Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines
4. Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Overview at a Glance
4.1. Neoantigen-based Personalized Cancer therapeutic Vaccines-Region Wise Total Market Share (%) Distribution by 2035
4.2. Neoantigen-based Personalized Cancer therapeutic Vaccines-Indication Wise Total Market Share (%) Distribution by 2035
5. Neoantigen-based Personalized Cancer therapeutic Vaccines
5.1. Introduction
5.1.1. Tumor neoantigens: from basic research to clinical applications
5.1.2. Historical overview in the understanding of tumor neoantigens
5.1.3. Neoantigens-directed immunoediting and immune escape
5.1.4. Overview of Preclinical and clinical neoantigen vaccine-based studies
5.1.4.1. Neoantigen-based adoptive T cell transfer
5.1.4.2. Neoantigen-based cancer vaccines
5.1.4.3. Combination of neoantigen vaccine with other therapies
5.1.4.3.1. Biomarker for immune checkpoint inhibitors
5.1.4.3.2. Resistance mechanism for immune checkpoint inhibitors
5.1.5. Identification and prediction of neoantigens
5.1.6. Principle of neoantigen vaccines
5.1.7. Clinical progress
5.1.8. Pros and Cons
6. Unmet Needs
7. Emerging Therapies
7.1. Key Cross Competition
7.2. Tedopi (OSE2101): OSE Immunotherapeutics
7.2.1. Product Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology
7.3.1. Product Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. GEN-009 Adjuvanted Vaccine: Genocea Biosciences
7.4.1. Product Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. TG01 Vaccine: Targovax
7.5.1. Product Description
7.5.2. Other Developmental Activities
7.5.3. Clinical Development
7.5.4. Safety and Efficacy
7.5.5. Product Profile
7.6. iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics
7.6.1. Product Description
7.6.2. Other Developmental Activities
7.6.3. Clinical Development
7.6.4. Safety and Efficacy
7.6.5. Product Profile
7.7. NEO-PV-01: Neon Therapeutics
7.7.1. Product Description
7.7.2. Other Developmental Activities
7.7.3. Clinical Development
7.7.4. Safety and Efficacy
7.7.5. Product Profile
List to be continued in report…
8. Neoantigen-based Personalized Cancer therapeutic Vaccines: Seven Major Market Analysis
8.1. Key Findings
8.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size in 7MM
9. 7MM: Market Outlook
9.1. United States: Market Size
9.1.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in the United States
9.1.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in the United States
9.2. EU-5 countries: Market Size and Outlook
9.2.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in EU5 Countries
9.2.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in EU5 Countries
9.3. Japan Market Outlook
9.3.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in Japan
9.3.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in Japan
10. Attribute analysis
11. KOL Views
12. Market Drivers
13. Market Barriers
14. Future Outlook
15. Appendix
15.1. Bibliography
15.2. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/